Oral anti-diabetic drugs

ApprovedSmall molecule

Oral anti-diabetic drugs is one of 70 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Acute DiarrheaActive, not recruiting

Type 2 DiabetesApproved

Type 2 Diabetes MellitusApproved

Active, not recruiting

Acute DiarrheaApproved

Active, not recruiting

Type 2 DiabetesApproved

Approved

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Oral anti-diabetic drugs

Sanofi

Approved

2 2

Glargine

Eli Lilly

Preclinical

8 3

Aurlumyn

BBTG International Inc.

Preclinical

1 4

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Forxiga

AstraZeneca

Preclinical

3 8

Lovaza

AstraZeneca

Preclinical

1 9

Acipimox

Boehringer Ingelheim

Preclinical

2 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Completed· Sanofi logo

Sanofi·Phase 3·NCT02749890·321 enrolled

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Completed· Sanofi logo

Sanofi·Phase 3·NCT02752828·521 enrolled

Transplantation1 trial

Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.

Unknown status·SSeoul National University Hospital·N/A·NCT01922492·28 enrolled

Pediatric1 trial

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Completed· Sanofi logo

Sanofi·Phase 3·NCT05794230·1,528 enrolled

Type 2 Diabetes Mellitus1 trial

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

Terminated· Sanofi logo

Sanofi·Phase 4·NCT00950534·25 enrolled

Acute Diarrhea1 trial

Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children

Completed· Sanofi logo

Sanofi·Phase 4·NCT02169817·629 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Oral anti-diabetic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral anti-diabetic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral anti-diabetic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Oral anti-diabetic drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

Transplantation1 trial

Pediatric1 trial

Type 2 Diabetes Mellitus1 trial

Acute Diarrhea1 trial

References

Drug Info

Quick Facts

Related News